Caffeinol

TAKE ACTION TO TELL THE TTB & CONGRESS TO REQUIRE CANCER WARNING LABELS ON ALL BEVERAGE ALCOHOL PRODUCTS SAN RAFAEL, Calif., Jan. 4, 2025 /PRNewswire/ -- Alcohol Justice is commending United States Surgeon General Vivek Murthy for releasing the Alcohol and Cancer Risk Report. Continue Reading (PRNewsfoto/Alcohol Justice) The report released January 3, 2025, documents alcohol's role in causing cancer which is becoming clearer each year. With this important publication, the Surgeon General has joined the chorus of researchers and advocates in flagging the risk and calling attention to alcohol's status as one of the leading behavioral risk factors for cancer. The report also urges Congress to reconsider the existing outdated cancer warning labels. The report shines stark light on how current federal policy has failed U.S. residents, falling well short of the state of medical knowledge and leaving most alcohol consumers to either educate themselves or die trying. Alcohol use brings on a variety of cancers, attacking the liver, colon, breast, throat, and esophagus, among others. The report estimates that, over a decade, nearly 1 million cancer cases are caused by alcohol in the United States—and 1 out of 6 develop in drinkers who are consuming within the current federal recommendations. The risk hits women particularly hard, as nearly 60% of alcohol-related cancer deaths are due to breast cancer. The cancer danger starts rising with any alcohol consumption at all, confirming the international Global Burden of Disease collaborative's consensus findings: there is no risk-free level of alcohol consumption. "The research showing positive health effects from alcohol consumption are mostly a function of bad science corrupted by industry," stated Rob Lipton,PhD, Development Director at Alcohol Justice. "There is no dose response effect found for this supposed benefit while alcohol consumption related harms have been repeatedly shown." The clearly spelled out risk in the new report calls greater attention for the need for a revised alcohol warning label. The current label, imposed by the federal government has not been modified in 35 years, despite the fact that the act mandating it also called for it to be revised as new information became available. In 2025, the long-delayed label update now can be readily informed by the current alcohol-cancer report so that the clear danger can be stated. The current, very outdated label, only acknowledges that alcohol "may cause health problems." This is far from satisfactory given the generally accepted scientific understanding of increased cancer risk. There are other important improvements needed for a revised label: The current label suffers from poor legibility, a lack of graphical or colorful elements, and a single, monotonous message than encourages "warning fatigue." As the new Congress is sworn in, they should make it a priority to embrace the current best practices for protecting public health: promoting cancer risk information, properly informing consumers of the products' risks, and understand that the industry's messages will never be in the public's interest. California's Prop 65 California already has a warning system in place, but it remains unsatisfactory. Although Prop 65-mandated signs at points-of-sale for alcoholic beverages warning that alcohol can cause cancer may be responsible for California residents having a greater awareness of the risk than the general U.S. population, this awareness remains low. The signs themselves are low-impact, often poorly maintained, and exempt from the on-package requirements of other CA-specific cancer warnings. Moreover, the increasing prevalence of online sales has given retailers opportunity to evade the requirement, and enforcement is arcane and often absent.] Alcohol is one of the leading behavioral risk factors for cancers, behind only tobacco use and obesity. That risk starts increasing with the first sip. Women bear outsized risk, as around 60% of alcohol-related cancer deaths in women are due to breast cancer. Only 45% of U.S. residents are aware of the alcohol-cancer link. Current U.S. warning labels have not kept up with best practices for product health advisories. Creating an impactful warning starts with congressional action—the incoming class has this opportunity to make their mark. TAKE ACTION Tell the U.S. Alcohol and Tobacco Tax and Trade Bureau (TTB) and your members of Congress it's time to raise the public's awareness about the serious risks of consuming alcoholic beverages by requiring cancer warning labels on all alcohol containers and packaging, and on all alcohol advertising and marketing materials. Click here to TAKE ACTION. SOURCE Alcohol Justice WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Company recently signed a non-binding term sheet with Dr Glitter Pty Ltd for mutual development in ActivCrystal™ Format Vancouver, Canada, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, recently announced that it signed a non-binding term sheet with Dr. Glitter Pty Ltd, a health technology company that has developed ActivCrystal™ technology, a world-first oral delivery format that encapsulates active ingredients in crystals that are tasteless, odorless, made from natural ingredients, and designed to be sprinkled on meals. The two companies plan to collaborate on the development and commercialization of Clearmind’s proprietary MEAI-based alcohol substitute and Dr Glitter Pty Ltd’s proprietary ActivCrystal™ technology. The term sheet outlines preliminary terms that, upon the mutual agreement of the parties, will be memorialized in a definitive agreement that sets forth a framework for advancing Clearmind and Dr Glitter Pty Ltd’s groundbreaking innovations. As recently announced, under the terms of the term sheet, upon the execution of the definitive agreement, the parties will work together to develop MEAI-based alcohol alternative aimed to naturally replicate the known sensations from drinking alcohol without the associated health risks or hangover. In ActivCrystal™ format, Clearmind’s MEAI-based alcohol alternative may be sprinkled into users’ choice of beverage or food, and dosage may be varied by users individually. This collaboration has the potential to mark an important milestone in Clearmind’s strategy to bring MEAI to global markets, addressing the urgent need for innovative solutions to combat alcohol misuse - a major contributor to countless annual deaths worldwide. “We are thrilled to partner with Dr Glitter to advance the development of MEAI as a safe alternative to alcohol,” said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine. “In parallel to advancing our clinical program with MEAI, we are actively developing our alcohol alternative product, designed to provide some of the enjoyable sensations and experiences associated with alcohol, without the alcohol itself. By offering a solution that adults can enjoy without the harmful effects of alcohol, we aim to transform the landscape of social drinking. We believe that partnering with innovative companies in this field is the right approach to drive thi change forward.” About Clearmind Medicine Inc. Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The Company’s intellectual portfolio currently consists of nineteen patent families including 29 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.” For further information visit: https://www.clearmindmedicine.com or contact: Investor Relations invest@clearmindmedicine.com Telephone: (604) 260-1566 US: CMND@crescendo-ir.com General Inquiries Info@Clearmindmedicine.com www.Clearmindmedicine.com About Dr Glitter Pty Ltd Dr Glitter Pty Ltd is a health technology company that has developed ActivCrystal™ technology, a world-first oral delivery format that encapsulates active ingredients in crystals that are tasteless, odourless, made from natural ingredients, and designed to be sprinkled on meals. The Company has submitted its international patent application for the use cases, manufacturing processes, and compositions of ActivCrystals™. The product format has been commercialised under the Dr Glitter™ brand, and has extensive potential applications in dietary supplements, pet supplements, therapeutic drugs, and in geriatric and paediatric medicine. The company also intends to license its product format to brands and manufacturers globally. For further information, please contact info@activcrystal.com To learn more about the Dr Glitter™ brand, please visit www.drglitter.com Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the execution of definitive agreements with Dr. Glitter PTY Ltd., the potential collaboration and partnership with Dr. Glitter PTY Ltd., its strategy to bring MEAI to global markets, its aims to transform the landscape of social drinking and its belief that that partnering with innovative companies in the alcohol alternative and substitute market is the right approach to change the face of social drinking. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2023 filed with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.